Loading…

Molecular Systems Pharmacology: Isoelectric Focusing Signature of Protein Kinase Cδ Provides an Integrated Measure of Its Modulation in Response to Ligands

Protein kinase C (PKC), a validated therapeutic target for cancer chemotherapy, provides a paradigm for assessing structure–activity relations, where ligand binding has multiple consequences for a target. For PKC, ligand binding controls not only PKC activation and multiple phosphorylations but also...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2014-06, Vol.57 (12), p.5356-5369
Main Authors: Kedei, Noemi, Chen, Jin-Qiu, Herrmann, Michelle A, Telek, Andrea, Goldsmith, Paul K, Petersen, Mark E, Keck, Gary E, Blumberg, Peter M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Protein kinase C (PKC), a validated therapeutic target for cancer chemotherapy, provides a paradigm for assessing structure–activity relations, where ligand binding has multiple consequences for a target. For PKC, ligand binding controls not only PKC activation and multiple phosphorylations but also subcellular localization, affecting subsequent signaling. Using a capillary isoelectric focusing immunoassay system, we could visualize a high resolution isoelectric focusing signature of PKCδ upon stimulation by ligands of the phorbol ester and bryostatin classes. Derivatives that possessed different physicochemical characteristics and induced different patterns of biological response generated different signatures. Consistent with different patterns of PKCδ localization as one factor linked to these different signatures, we found different signatures for activated PKCδ from the nuclear and non-nuclear fractions. We conclude that the capillary isoelectric focusing immunoassay system may provide a window into the integrated consequences of ligand binding and thus afford a powerful platform for compound development.
ISSN:0022-2623
1520-4804
DOI:10.1021/jm500417b